Revenues (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue by Product and by Geographic Area

Revenues were as follows (in millions):

	Three months ended March 31,
	2024						2023
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	657	$	342	$	999	$	623	$	304	$	927
ENBREL	561		6		567		564		15		579
XGEVA	366		195		561		384		152		536
Repatha	273		244		517		197		191		388
TEPEZZA(1)	419		5		424		—		—		—
Otezla	293		101		394		294		98		392
KYPROLIS	234		142		376		234		124		358
Aranesp	100		249		349		115		240		355
EVENITY	236		106		342		164		90		254
Nplate	190		127		317		246		116		362
Vectibix	120		127		247		111		122		233
BLINCYTO	153		91		244		126		68		194
KRYSTEXXA(1)	235		—		235		—		—		—
TEZSPIRE(2)	173		—		173		96		—		96
Other products(3)	963		410		1,373		821		351		1,172
Total product sales(4)	$	4,973	$	2,145	7,118		$	3,975	$	1,871	5,846
Other revenues					329						259
Total revenues					$	7,447					$	6,105

____________

(1)    TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.

(2)    TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.

(3)    Consists of product sales of our non-principal products.

(4)    Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2024 and 2023.